Top

Published in:

01-09-2020 | Systemic Lupus Erythematosus | Case Based Review

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review

Authors: Feng He, Qingqing Luo, Ming Lei, Lixin Fan, Xinning Shao, Kaiyuan Hu, Shuguang Qin, Na Yu, Jie Cao, Liuping Yang

Published in: Clinical Rheumatology | Issue 9/2020

Abstract

COVID-19 has become a global concern. A large number of reports have explained the clinical characteristics and treatment strategies of COVID-19, but the characteristics and treatment of COVID-19 patient with systemic lupus erythematosus (SLE) are still unclear. Here, we report the clinical features and treatment of the first SLE patient with confirmed COVID-19 pneumonia. This was a 39-year-old woman, diagnosed with SLE 15 years ago, whose overall clinical characteristics (symptoms, laboratory tests, and chest CTs) were similar to those of the general COVID-19 patients. She continued to take the previous SLE drugs (doses of glucocorticoids, hydroxychloroquine, and immunosuppressive agents were not reduced) and was treated with strict antiviral and infection prevention treatment. After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy. Finally, this long-term immune suppressive patient’s COVID-19 was successfully cured. The successful recovery of this case has significant reference value for the future treatment of COVID-19 patients with SLE.

Key Points

• COVID-19 patients with SLE is advocated to continue the medical treatment for SLE.

• Hydroxychloroquine may have potential benefits for COVID-19 patients with SLE.

• COVID-19 patients with SLE is prone to relapse, and multiple follow-ups are necessary.

COVID-19 cases worldwide. Available from: https://www.worldometers.info/coronavirus/. Accessed 30 Apr 2020

Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358(9):929–939CrossRef

Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, Nochy D, Debré P, Piette JC, Gorochov G (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175(12):8392–8400CrossRef

Yang J, Yang X, Zou H, Chu Y, Li M (2011) Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford) 50(8):1366–1372CrossRef

Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L et al (2020) The CD38/NAD/SIRTUIN1/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep 30(1)

Gordon C, Amissah-Arthur M-B, Gayed M, Brown S, Bruce IN, D'Cruz D et al (2018) The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 57(1)

Sawalha AH, Zhao M, Coit P, Lu Q (2020) Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 215:108410CrossRef

Michaud K, Wipfler K, Shaw Y, Simon TA, Cornish A, England BR, Ogdie A, Katz P (2020) Experiences of patients with rheumatic diseases in the US during early days of the COVID-19 pandemic. ACR Open Rheumatol

Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JIP, Potential Rapid Diagnostics et al Vaccine and Therapeutics for 2019 Novel coronavirus (2019-nCoV): a systematic review. J Clin Med 2020, 9(3)

10.

Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, Chen Z, Chen G (2020) Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant

11.

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF et al (2020) On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis & rheumatology (Hoboken, NJ)

12.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3(11):722–727CrossRef

13.

Gao J, Tian Z, Yang X (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72–73CrossRef

14.

(2020) Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43(3):185–188

15.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271CrossRef

16.

Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63(3):457–460CrossRef

17.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69CrossRef

18.

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol

19.

FDA Issues FAQs on Emergency Use Authorization for Hydroxychloroquine and Chloroquine. Available from: https://www.rheumatology.org/Portals/0/Files/FAQs-EUA-Chloroquine-Phosophate-Hydroxychloroquine-Sulfate-Certain-COVID-19-Patients.pdf. Accessed 27 Apr 2020

20.

Yazdany J, Kim AHJ (2020) Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med 172:754–755CrossRef

21.

EULAR guidance for patients during Covid-19 outbreak. Mar 17, 2020. Available from: https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm. Accessed 27 Apr 2020

22.

BSR guidance for patients during Covid-19 outbreak. Apr 23, 2020. Available from: https://www.rheumatology.org.uk/News-Policy/Details/Covid19-Coronavirus-update-members. Accessed 27 Apr 2020

23.

Australian Rheumatology Association guidance for patients during Covid-19 outbreak. Mar 17, 2020. Available from: https://arthritisaustralia.com.au/advice-regarding-coronavirus-covid-19-from-the-australian-rheumatology-association/. Accessed 27 Apr 2020

24.

ACR guidance for patients during Covid-19 outbreak. Apr 14, 2020. Available from: https://www.rheumatology.org/announcements. Accessed 27 Apr 2020

25.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis

26.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420–422CrossRef

27.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y (2020) Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 221:1762–1769CrossRef

28.

Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, Peng L (2020) Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis 93:297–299CrossRef

29.

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270–273CrossRef

30.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395(10224):565–574CrossRef

31.

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720CrossRef

32.

National Health Commission of the People’s Republic of China. Chinese diagnosis and treatment guideline for COVID-19 (version 6.0). Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817. Accessed 27 Apr 2020

33.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229):1054–1062CrossRef

34.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med

35.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395(10223):497–506CrossRef

Title: Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review
Authors: Feng He
Qingqing Luo
Ming Lei
Lixin Fan
Xinning Shao
Kaiyuan Hu
Shuguang Qin
Na Yu
Jie Cao
Liuping Yang
Publication date: 01-09-2020
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
SARS-CoV-2
COVID-19
Hydroxychloroquine
Published in: Clinical Rheumatology / Issue 9/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05230-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2020

Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology

Challenges in delivering rheumatology care during COVID-19 pandemic

FDG PET/CT used in identifying adult-onset Still’s disease in connective tissue diseases

Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus

Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study

Large vessel disease as a potentially treatable cause of devastating critical digital ischaemia in systemic sclerosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page